Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937364 · ClinicalTrials.gov registry record · Phase 2
Preventing Alcohol Withdrawal With Oral Baclofen
A Phase 2 study, sponsored by Essentia Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01937364 is a Phase 2 study that was terminated before completion, run by Essentia Health. The registered enrollment target is 17 participants.
The verdict
NCT01937364, a Phase 2 study, was terminated before completion, sponsored by Essentia Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS. This medication is most often used for patients who have spasticity of their muscles due to a neuromuscular disease. In several European studies, and in an earlier study at Essentia Health (NCT00597701), baclofen has been found to have a significant effect on the severity of symptoms of AWS.
Interventions
- DRUG Placebo
- DRUG Baclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01937364
The ClinicalTrials.gov registry entry for NCT01937364 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Essentia Health, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01937364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01937364 about?
NCT01937364 is a clinical study titled "Preventing Alcohol Withdrawal With Oral Baclofen". The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS. This medication is most often used for patients who have spasticity of their muscles due to a neuromuscular disease. In...
What is the current status of trial NCT01937364?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2013-11. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01937364?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT01937364?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.